Foventa Adds Medical and Financial Leads for Phase IIb Push
Cambridge-based Foventa Therapeutics has expanded its leadership team, naming Dr. Zaiba Malik as Chief Medical Officer and Julia Jones as Chief Financial Officer. The new executives join CEO Olav Hellebø to steer the company’s lead asset, FOV407, through a critical Phase IIb trial and upcoming Series A funding round.
Dr. Malik brings two decades of experience in clinical ophthalmology and drug development, having most recently served as Global Medical Director at Medpace. Her background includes clinical practice and humanitarian work, which the company expects to provide essential insights as it develops FOV407. This program aims to replace invasive eye injections with a topical treatment for non-proliferative diabetic retinopathy.
Julia Jones, a Chartered Accountant formerly with PWC, joins with a history of scaling biotech firms across the US and Europe. Her track record includes managing approximately £1.5 billion in venture capital for companies such as PepGen and MiroBio. Together with Malik, she will focus on securing the financial stability required to transition the firm’s lead candidate from research into clinical application.
Comments (0)
No comments yet. Be the first!